Model‐based risk analysis of coupled process steps

A section of a biopharmaceutical manufacturing process involving the enzymatic coupling of a polymer to a therapeutic protein was characterized with regards to the process parameter sensitivity and design space. To minimize the formation of unwanted by‐products in the enzymatic reaction, the substrate was added in small amounts and unreacted protein was separated using size‐exclusion chromatography (SEC) and recycled to the reactor. The quality of the final recovered product was thus a result of the conditions in both the reactor and the SEC, and a design space had to be established for both processes together. This was achieved by developing mechanistic models of the reaction and SEC steps, establishing the causal links between process conditions and product quality. Model analysis was used to complement the qualitative risk assessment, and design space and critical process parameters were identified. The simulation results gave an experimental plan focusing on the “worst‐case regions” in terms of product quality and yield. In this way, the experiments could be used to verify both the suggested process and the model results. This work demonstrates the necessary steps of model‐assisted process analysis, from model development through experimental verification. Biotechnol. Bioeng. 2013; 110:2462–2470. © 2013 Wiley Periodicals, Inc.

[1]  D Petrides,et al.  Computer-aided process analysis and economic evaluation for biosynthetic human insulin production-A case study. , 1995, Biotechnology and bioengineering.

[2]  Hervé Broly,et al.  Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: towards a global multi-step design space. , 2012, Journal of pharmaceutical sciences.

[3]  Sunil Chhatre,et al.  Global sensitivity analysis for the determination of parameter importance in the chromatographic purification of polyclonal antibodies , 2008 .

[4]  J A Asenjo,et al.  Application of chromatographic theory for process characterization towards validation of an ion‐exchange operation , 2007, Biotechnology and bioengineering.

[5]  Karin Westerberg,et al.  Model‐Based Process Challenge of an Industrial Ion‐Exchange Chromatography Step , 2012 .

[6]  Sunil Chhatre,et al.  Global Sensitivity Analysis for the determination of parameter importance in bio‐manufacturing processes , 2008, Biotechnology and applied biochemistry.

[7]  Giancarlo Tonon,et al.  Enzymatic techniques for PEGylation of biopharmaceuticals , 2009 .

[8]  N. J. Titchener-Hooker,et al.  The use of windows of operation as a bioprocess design tool , 1996 .

[9]  Anita M. Katti,et al.  Fundamentals of Preparative and Nonlinear Chromatography , 1994 .

[10]  V. S. Vaidhyanathan,et al.  Transport phenomena , 2005, Experientia.

[11]  Y H Zhou,et al.  Visualizing integrated bioprocess designs through "windows of operation". , 1999, Biotechnology and bioengineering.

[12]  Anurag S Rathore,et al.  Roadmap for implementation of quality by design (QbD) for biotechnology products. , 2009, Trends in biotechnology.

[13]  Marcel Ottens,et al.  Design strategies for integrated protein purification processes: challenges, progress and outlook , 2008 .

[14]  F. Veronese,et al.  PEGylated Protein Drugs: Basic Science and Clinical Applications , 2009 .

[15]  Patrick Thompson,et al.  Defining process design space for monoclonal antibody cell culture , 2010, Biotechnology and bioengineering.

[16]  Tingyue Gu,et al.  Mathematical modeling and scale-up of size-exclusion chromatography , 1998 .

[17]  A. Rathore,et al.  Quality by design for biopharmaceuticals , 2009, Nature Biotechnology.

[18]  Cameron Alexander,et al.  Synthetic polymers for biopharmaceutical delivery , 2011 .